SERVICES

Preclinical

Plan your next preclinical study or partner with us for an IND/CTA-enabling package to get you from research to clinical trials faster. Save up to 30% on your preclinical timeline.

Learn More

Trending Topics

DISEASE MODELS

Oncology Models and Cell Lines

Advance your preclinical oncology compounds with a comprehensive suite of preclinical oncology studies, including in vitro and in vivo pharmacology efficacy models, in vivo imaging technologies as well as focal radiation capabilities.

ADMINISTRATION ROUTE

Inhalation Testing Capabilities

Inhalation toxicology studies are becoming vital in assessing the safety and potential toxicity of inhaled drugs or chemicals as respiratory diseases including asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) become more common.

PROGRAMMATIC DEVELOPMENT

IND/CTA-Enabling Packages

Accelerate your molecule’s success with Early Phase Development solutions that help to advance your molecule swiftly through critical milestones while maximizing the asset's value. Shave off as much as 30% on your early drug development timeline.

MARKETPLACE

Find the Right Partner

Find the right partner with the desire and resources to help you realize your asset’s potential. Through our private, secure and exclusive online portal, you can share information about your asset to attract potential investors or partners. It's one more innovative way to transform your program.

Preclinical Facilities & Locations

Enjoy global support and capacity for your preclinical studies with labs strategically positioned around the world. View all facilities.

Unleash the Power of Connected Insights

The landscape of development is becoming more complex. You still need your studies delivered on-time and on-budget. By connecting inspiring science with data, our committed scientific teams uncover insights from preclinical and clinical studies to help you reach your development milestones.

By the Numbers

Preclinical supported 81% of the FDA's 2019 NDA/BLA drugs
Preclinical supported 77% of the FDA's 2019 biologics
Save up to 30% on your preclinical timeline
More than 125 billion SEND data points submitted

Have Questions?

TESTIMONIAL

“A dependable and reliable source for complicated studies with dedicated and extremely competent study direction.”

–Project leader from a global pharmaceutical company

Covance Insights

Treating Age-Related Macular Degeneration (AMD) With a Novel Stem Cell Therapy
Treating Age-Related Macular Degeneration (AMD) With a Novel Stem Cell Therapy
Blogs
The Audacious Goals Initiative (AGI) for regenerative medicine is a program run by the National Eye Institute (NEI), aimed at finding new therapies for eye diseases that remain difficult to treat. Age-related macular degeneration is the leading cause of vision loss in the US, affecting 2.5% of the population, most over the age of 50.
Read More
A comparison of FDA, EMA & PMDA regulatory guidance for in vitro drug-drug interaction (DDI) assessments
A comparison of FDA, EMA & PMDA regulatory guidance for in vitro drug-drug interaction (DDI) assessments
Blogs
This whitepaper article explores the 2020 regulatory changes in U.S. FDA guidance1 and recommendations, compared to existing EU EMA2 and Japanese PMDA3 guidance for in in vitro drug-drug interaction (DDI) assessments. The Evolving Regulatory Landscape Since 1997 the regulatory agencies, FDA, EMA and PMDA have endorsed the use of in vitro metabolism studies to assess the DDI potential of new chemical entities (NCE). Over the past 10 years, however, scientific progress has been rapid, fueled by sophisticated in vitro models and in silico predictive programs.
Read More
Assessment of Potential Drug-Drug Interactions from In Vitro Experiments to PBPK Modeling
Assessment of Potential Drug-Drug Interactions from In Vitro Experiments to PBPK Modeling
Videos & Webinars Play Video
The FDA recently approved updated regulatory guidance for drug-drug interactions (DDIs). This webinar will focus on how to follow the FDA guidance, design in vitro studies, interpret the data and assess potential drug-drug interactions, using both static and Physiologically Based Pharmacokinetic (PBPK) models. We will also share our interpretations, as regulatory agencies recommend different approaches for calculation of the DDI potentials including static and PBPK models. Co-administration of multiple drugs may potentially cause a drug-drug interaction (DDI) in which one drug alters the exposure of another, resulting in either therapeutic failure or risk of a patient's life. In vitro studies are key to assessing potential DDIs because they are cost-effective, time-saving and can help to understand the mechanisms of DDI and provide directives to clinical trials (clinical trials should not be used to screen potential DDIs because of high costs, lengthy duration and ethical considerations, but they should be used to confirm potential DDIs recommended from in vitro studies and corresponding modeling).
Read More
In Vitro Cytokine Release Assays: Is There Calm After the Storm? | CRA Post I
In Vitro Cytokine Release Assays: Is There Calm After the Storm? | CRA Post I
Blogs
Cytokine Release Syndrome (CRS), otherwise known as cytokine storm, is a systemic inflammatory response caused by complications due to disease, infection or an adverse effect of biologic therapy. The clinical symptoms of a cytokine storm are massive release of a potent cocktail of pro-inflammatory cytokines into the general circulatory system, leading to severe multi-organ damage, failure or potentially death. This is an extremely unwanted immunotoxicological side effect in drug development.
Read More

SING UP NOW!

Get the latest scientific content updates from Covance Preclinical to your inbox.

Learn More